S2-E27.1 - previewing International nASH day 2021 -- overview of events
Send us a text Global Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. This conversation provides and overview of the day's event. The 4th annual International NASH Day is a major global institution, with endorsements from WHO, EASL, AASLD, at least 14 medical societies, and organizations in at least 26 countries, and more than 100,000 people tuning in at some point during the day. In this conversation, Donna Cryer provides an overview of...
29 Touko 202114min
S2 - E28 - SPECIAL EPISODE: What Can We Learn The Aldafermin Discontinuation In F2/F3 NASH?
Send us a text Roger Green narrates a series of interviews, conversations and viewpoints about NGM Biopharmaceuticals discontinuing its F2/F3 aldafermin program The SurfingNASH team weaves interviews, conversations and text notes from 9 stakeholders, including US and EU KOLs, program heads, treating physicians, patient advocates and NASH patients into a narrative addressing key issues. Was the ALPINE 2/3 trial a clinical failure? What commercial considerations might have played into NGM BIo's...
27 Touko 202125min
S2-E27 - Previewing International NASH Day -- a growing Day of Global Education and Organizing
Send us a text Global Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. Last year's IND had 100+ participants. This year will be bigger! Learn why. The 4th annual International NASH Day is a major global institution, with endorsements from WHO, EASL, AASLD, at least 14 medical societies, and organizations in at least 26 countries. Global Liver Institute President and CEO Donna Cryer rejoins the Surfers to discuss a day that starts at Midni...
27 Touko 202138min
S2-E26.3 - How much will real-life NASH treatment decisions depend on the specialty of the prescriber?
Send us a text azen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therapy after current Phase 2b and Phase 3 candidates have been approved. This conversation considers how the idea that front-line treaters will be PCPs might affect treatment patterns. This conversation starts with Roger Green pointing out that most real-world patient treatment decisions will be made by front-line, primary care physicians. Stephen Harrison proposes one more applica...
23 Touko 202118min
S2-E26.2 - How simply "Vertebrate" will future NASH therapy be?
Send us a text Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversation examines the prospect for different kinds of backbone strategies. At one extreme, many chronic therapies have a single monotherapy backbone agent, like what metformin has been to Type 2 diabetes. At the other, there are diseases where prescribers start with multiple different agents, or ...
22 Touko 202114min
S2-E26.1 - What will NASH Pharmacotherapy Look Like When we have Multiple Options?
Send us a text Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversation lays out basic premises. In this conversation, Stephen Harrison and Mazen focus on how treatment guidelines and therapeutic choices might vary for patients starting at F2 vs. F3 vs. compensated (maybe even decompensated?) cirrhosis. One key issue is "de-escalation" -- whether guidelines ...
22 Touko 202112min
S2-E26 - What Will Treatment Pathways Look Like For NASH Patients?
Send us a text Mazen Noureddin joins the Surfers to explore the issues and needs that will shape treatment guidelines in a world after NASH drugs come to market. In Season 2 Episode 16, a discussion of cost-effectiveness led to the question, "How will treatment pathways and rules evolve as new NASH drugs come to market." Mazen Noureddin, who raised this issue with Stephen Harrison in the earlier episode, returns to explore the answer ten episodes later. The discussion considers what the phras...
20 Touko 202150min
S2-E25.1 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- Key Findings
Send us a text (This episode has been reposted to include the complete conversation content.) Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gowrieh share key findings from their 20210 Journal of Hepatology paper titled "Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort." The 2021 Journal of Hepatology paper "Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and st...
17 Touko 202114min
